首页 | 本学科首页   官方微博 | 高级检索  
检索        

何氏养肾方对肾病综合征大鼠模型的抗炎作用
引用本文:邓丽娥,李强,董明国,何世东,林捷,钟云良,方倩瑜,匡彬.何氏养肾方对肾病综合征大鼠模型的抗炎作用[J].广州中医药大学学报,2017,34(6).
作者姓名:邓丽娥  李强  董明国  何世东  林捷  钟云良  方倩瑜  匡彬
作者单位:广东省东莞市中医院,广东东莞,523000
基金项目:东莞市科技局科研项目,广东省中医药局科研项目
摘    要:【目的】探讨何氏养肾方对阿霉素所致肾病综合征大鼠的抗炎作用。【方法】采用一次性尾静脉注射阿霉素建立肾病综合征大鼠模型。将59只造模成功的大鼠,随机分为模型组(N=11),阳性对照组(N=12),中药高、中、低剂量组(各组N=12),另选取10只正常大鼠为正常组。造模2周后,开始给药,正常组、模型组大鼠给予等体积生理盐水灌胃;阳性对照组给予贝那普利片水溶液灌胃,前15 d剂量为10 mg·kg-1·d-1,后15 d剂量为20 mg·kg~(-1)·d~(-1);中药高、中、低剂量组大鼠给予何氏养肾方水煎液灌胃,剂量分别为33.26、16.63、8.32 g·kg~(-1)·d~(-1);用药时间持续30 d。治疗期间观察大鼠一般情况;给药结束后,应用生化分析仪测定各组大鼠24 h尿蛋白定量、尿蛋白、尿肌酐水平,采用酶联免疫吸附(ELISA)法检测各组大鼠血清超敏C反应蛋白(Hs-CRP)表达水平,采用免疫组化法检测各组大鼠肾组织细胞间粘附分子-1(ICAM-1)、血管细胞粘附分子-1(VCAM-1)表达。【结果】造模后大鼠体质量增长较正常组均显著减缓(P0.01)。与正常组比较,模型组大鼠24 h尿蛋白定量、血清Hs-CRP、肾组织ICAM-1、VCAM-1表达水平均显著升高(P0.05或P0.01);与模型组比较,阳性对照组和中药高剂量组大鼠24 h尿蛋白定量显著降低(P0.05),阳性对照组和中药各治疗组大鼠血清HsCRP、肾组织ICAM-1、VCAM-1表达水平显著降低(P0.05或P0.01)。【结论】何氏养肾方对阿霉素肾病综合征大鼠有一定的抗炎作用,其机制可能与降低肾组织ICAM-1、VCAM-1表达有关,其中高剂量的何氏养肾方疗效更好。

关 键 词:何氏养肾方/药理学  肾病综合征/中药疗法  ICAM-1  VCAM-1  疾病模型  动物  大鼠

Anti-inflammatory Actions of Heshi Yangshen Recipe on Rat Model of Nephrotic Syndrome
DENG Li-E,LI Qiang,DONG Ming-Guo,HE Shi-Dong,LIN Jie,ZHONG Yun-Liang,FANG Qian-Yu,KUANG Bin.Anti-inflammatory Actions of Heshi Yangshen Recipe on Rat Model of Nephrotic Syndrome[J].Journal of Guangzhou University of Traditional Chinese Medicine,2017,34(6).
Authors:DENG Li-E  LI Qiang  DONG Ming-Guo  HE Shi-Dong  LIN Jie  ZHONG Yun-Liang  FANG Qian-Yu  KUANG Bin
Abstract:Objective To explore the anti-inflammatory action of Heshi Yangshen Recipe on rat model of nephrotic syndrome induced by adriamycin. Methods Rat model of nephrotic syndrome was established by tail venous injection of one-dose of adriamycin. SD rats were divided into normal group(N = 10),model group(N =11), positive control group (N = 12), and high-, middle- , low-dose Chinese medicine groups (N = 12, respectively). Two weeks after modeling,rats in the normal group and model group were given gastric gavage of same volume of normal saline, rats in positive control group were given gastric gavage of benazepril aqueous solution at a dose of 10 mg·kg-1·d-1 in the former period of 15 days and at 10 mg·kg-1·d-1 in the later period of 20 days, and rats in high-,middle- ,low-dose groups were given gastric gavage of Heshi Yangshen Recipe at a dosage of 33.26, 16.63, 8.32 g·kg-1·d-1 respectively, for 30 continuous groups. During the treatment period, the general situation of rats was observed. After the completion of medication, the levels of 24-hour urinary protein, urine total proteins, urine creatinine were measured by biochemical analyzer, serum high-sensitivity C-reactive protein (Hs-CRP) level was detected by enzyme-linked immunosorbent assay(ELISA),and the expression levels of intercellular adhesion molecule 1 (ICAM-1)and vascular cell adhesion molecule-1 (VCAM-1)in rat renal tissue of various groups were determined by immunohistochemistry. Results The increase of body mass in all of the modeled rats was significantly slowed down (P < 0.01 as compared with the normal group). Compared with the normal group, the levels of 24-hour urinary protein, serum hs-CRP, and the expression of ICAM-1 and VCAM-1 in rat renal tissue were increased in the model group (P < 0.05 or P <0.01). Compared with the model group, the level of 24-hour urinary protein in the positive control group and high-dose Chinese medicine group was decreased (P < 0.05), and the levels of serum Hs-CRP, and the expression of ICAM-1 and VCAM-1 in rat renal tissue of the positive control group and high-,middle-,low-dose Chinese medicine groups were decreased (P < 0.05 or P < 0.01). Conclusion Heshi Yangshen Recipe exerts certain anti-inflammatory action, and its mechanism may be related with the decrease of ICAM-1 and VCAM-1 expression. High dosage of Heshi Yangshen Recipe has the strongest therapeutic effect.
Keywords:Heshi Yangshen Recipe/pharmacology  nephrotic syndrome/TCD therapy  ICAM-1  VCAM-1  disease models  animal  rats
本文献已被 CNKI 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号